Despite more than three decades of intensive effort, no effective pharmacological inhibitors
of the RAS oncoproteins have reached the clinic, prompting the widely held perception that …

Mutationally activated and oncogenic versions of the ras genes were first identified in human
tumors in 1982. This discovery prompted great interest in the development of anti-Ras …

Abstract RAS (KRAS, NRAS and HRAS) is the most frequently mutated gene family in
cancers, and, consequently, investigators have sought an effective RAS inhibitor for more …

Abstract RAS GTPases (H-, K-, and N-RAS) are the most frequently mutated oncoprotein
family in human cancer. However, the relatively smooth surface architecture of RAS and its …

About a third of all human cancers harbor mutations in one of the K-, N-, or HRAS genes that
encode an abnormal RAS protein locked in a constitutively activated state to drive malignant …

RAS is the most frequently mutated oncogene in cancer and a critical driver of oncogenesis.
Therapeutic targeting of RAS has been a goal of cancer research for more than 30 years …

Introduction: The Ras proteins (K-Ras, N-Ras, and H-Ras) are GTPases that function as
molecular switches for a variety of critical cellular activities and their function is tightly and …

Ras proteins play a major role in human cancers but have not yielded to therapeutic attack.
Ras-driven cancers are among the most difficult to treat and often excluded from therapies …

RAS has long been viewed as undruggable due to its lack of deep pockets for binding of
small molecule inhibitors. However, recent successes in the development of direct RAS …

RAS genes are the most commonly mutated oncogenes in cancer, but effective therapeutic
strategies to target RAS-mutant cancers have proved elusive. A key aspect of this challenge …